The BHF CoRE Glasgow would like to congratulate Clinical Research Fellow Dr Su Ern Yeoh and the Heart Failure team for having successfully leveraged an award of £1.1million in Pharma funding from Astra Zeneca.
The funding was awarded in November 2020 and will be used for the implementation of the DAPA-RESIST clinical trial.
DAPA-RESIST is a multi-centre, open-label, randomised controlled clinical trial investigating Sodium glucose cotransporter-2 inhibitor DAPAgliflozin versus thiazide diuretic in patients with heart failure and diuretic RESISTance.
Dr Yeoh is supervised by Professor John McMurray, Professor Mark Petrie and Dr Ross Campbell.
For more information on DAPA-RESIST, please contact Dr Katriona Brooksbank - firstname.lastname@example.org
First published: 5 November 2020